Feb 6 |
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
|
Feb 5 |
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
|
Jan 5 |
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
|
Jan 2 |
Jasper Therapeutics to effect 1-for-10 reverse stock split
|
Jan 2 |
Jasper Therapeutics, Inc. Announces Reverse Stock Split
|
Dec 10 |
Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
|
Nov 30 |
Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
|
Nov 9 |
Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress
|
Nov 9 |
Jasper Therapeutics: Q3 Earnings Insights
|
Nov 9 |
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
|